Bordetella pertussis Antibody, IgM by ELISA with Reflex to Immunoblot
2001769
Ordering Recommendation
Evaluation of IgM pertussis antibodies has little clinical utility. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
Mnemonic
BORDM
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
Performed
Tue
Reported
1-8 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
 
Specimen Required
Patient Preparation
  
Collect
Serum separator tube.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute" or "convalescent."  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Contaminated, heat-inactivated, or severely lipemic specimens.  
Remarks
  
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)  
Reference Interval
 
 
Test Number Components Reference Interval
 Bordetella pertussis Antibody, IgM by ELISA 0.9 U/mL or less: Negative -​ No significant level of detectable Bordetella pertussis IgM antibody.
1.0-​1.1 U/mL: Equivocal -​ Repeat testing in 10-​14 days may be helpful.
1.2 U/mL or greater: Positive -​ IgM antibody to Bordetella pertussis detected, which may indicate a current or recent exposure/immunization to B. pertussis.
2004326Bordetella pertussis Antibody, IgM by Immunoblot  
 
Bordetella pertussis Antibody, IgM by Immunoblot
Effective February 19, 2013
Components Reference Interval
Bordetella pertussis Ab, IgM by Immunoblot Interp Negative
B. pertussis, IgM Immunoblot PT Negative
B. pertussis, IgM Immunoblot FHA Negative
Interpretive Data
Recommend that treatment decisions be based on the result of the B. pertussis IgM immunoblot test instead of the ELISA test. B. pertussis IgM test by ELISA may produce false-positive results.

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
 
Note
If Bordetella pertussis Antibody, IgM by ELISA is 1.2 U/mL or greater, then Bordetella pertussis IgM Immunoblot testing will be added. Additional charges apply.
CPT Code(s)
86615 Bordetella IgM; if reflexed add 86615 for Bordetella IgM Immunoblot
Components
Component Test Code*Component Chart NameLOINC
2001783B. pertussis Ab, IgM by ELISA42329-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • B. pertussis IgM reflex
  • Pertussis Antibody
  • Pertussis IgM Ab ELISA reflex to immunoblot